Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Minerva Neurosciences, Inc. NERV

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-293.4M
▼ 20492.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income 1.4
15M30M-30M-60M
20132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2021 · ROE -164.6%
-50%-100%-150%
201320192025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -23%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -24.7
-15M-30M
201320192025
Net buybacks $M Dividends $M
FY2017 · Dividends · · Net buybacks -1.1
-0.5M-1.0M
2017

Total assetsUSD 98.0M
EquityUSD -140.7M
CashUSD 82.3M
Current ratio36.28×

Equity funds -144% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NERV, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B◌0.00.00.00.00.00.00.00.0◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.00.0−0.1−0.1−0.0−0.0−0.0−0.1−0.0
EBITDA $B◌◌◌◌◌0.0−0.1−0.1−0.0−0.0−0.0−0.1◌
Income tax $B◌◌◌◌−0.0◌−0.00.0−0.00.00.0◌◌
Net income $B−0.30.0−0.0−0.0−0.00.0−0.1−0.1−0.0−0.0−0.0−0.1−0.0
Free cash flow $B◌◌◌−0.0◌◌◌◌0.0◌◌−0.0−0.0
EPS, diluted $−34.670.19−4.61−6.01−9.350.05−1.85−1.29−0.83−0.99−1.16−4.47−0.78
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %————−164.64.8−122.3−45.2−26.5−38.5−50.7−158.8−16.2
Shares out B0.040.010.010.010.040.040.040.040.040.040.020.020.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 52 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 12 checks were skipped: the balance sheet is not tagged before 2013. Six checks were skipped: EPS is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inMassachusetts
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image